Health Care • Medical/Dental Instruments
$7.02 ▲ +0.28
(+4.08%)
MKT CAP: $4.9M • VOL: 14.4K
52W L $7 52W H $26
ROARABLE / RQD
D • 50/100
PIOTROSKI
3 / 9
NVNO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$20.9M | -$23.8M | -$25.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$19.5M | -$21.8M | -$23.5M |
| EBITDA (Normalized) | -$20.9M | -$23.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$15.6M | -$16.8M | -$18.9M |
| Capital Expenditures (CapEx) | $5.0K | $37.0K | — |
| Free Cash Flow (FCF) | -$15.6M | -$16.9M | -$18.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.1M | $1.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $27.1M | $42.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NVNO.